Stephen Merrick, the Executive Chairman of NorthStar, expressed his happiness at having Barbara and David join the NorthStar Board. As we continue to concentrate on expanding NorthStar and satisfying the needs of patients who require better treatment options, Barbara’s vast experience holding senior finance and board positions in cutting edge pharmaceutical and biotech companies and David’s broad knowledge of the pharmaceutical industry and extensive experience in operations and quality functions will add invaluable perspectives. To fuel our progress, a number of crucial strategic decisions must be made. Barbara and David will offer knowledgeable advice for these crucial choices.
Ms. Bodem is a current board member, a former CFO of a publicly traded business, and she has vast international experience in branded and generic drugs, medical devices, and healthcare services and technology. She presently serves as a board director for BioMarin Pharmaceutical, Option Care Health, and Enovis Corporation. Ms. Bodem has formerly held director positions with Invacare Corporation, Syneos Health, and Turning Point Therapeutics. Additionally, she had increasingly responsible positions in finance at Eli Lilly, Hospira, Mallinckrodt Pharmaceuticals, and Hill-Rom, where she held the positions of SVP and CFO until the company was acquired in December 2021. Barbara obtained her MBA from Indiana University after earning a Bachelor of Science in Finance from the same institution.
As a leader in the company’s worldwide operations, quality, compliance, and remediation practices as well as life sciences practice, Mr. Keeling is currently a Senior Partner with McKinsey & Company, located in Chicago. David specializes in strategy, organization, mergers and acquisitions, operations, supply chain management, and has worked for McKinsey and clients in North America, Europe, and Asia. He has worked with the biggest and most prosperous biopharmaceutical firms for more than 25 years, covering fields like contract manufacturing, oncology, and gene and cell therapy. After earning a first-class engineering bachelor’s degree from the University of Western Australia, David went on to Northwestern University’s J.L. Kellogg Graduate School of Management to earn an MBA.
Late in 2023, NorthStar declared that it would concentrate its operations on providing the market with high-quality medical radioisotopes and expanding its radiopharmaceutical patient dose contract development and manufacturing organization (CDMO). This move was made to expedite growth and to have a more noticeable and immediate effect on the lives of patients suffering from cancer and other terminal illnesses.
Frank Scholz, Ph.D., President and CEO of NorthStar, stated that the company’s performance in 2024 and the ensuing years will be crucial. We think NorthStar can play a significant role as a catalyst for the global paradigm shift that is about to occur in the development and marketing of novel, effective radiodiagnostics and radiotherapies. The opportunities are huge as we move into this next phase of our evolution and growth, and having strong board members like David and Barbara who have a wealth of deep, diversified industry expertise will help us unlock the potential that our firm holds for our industry, doctors, and their patients.
NorthStar Medical Radioisotopes, LLC is one of the several wholly-owned subsidiaries of NorthStar Medical Technologies, a company headquartered in Beloit, Wisconsin. NorthStar Medical Radioisotopes is a commercial-stage radiopharmaceutical firm that is leading the way in improving patient care through the use of cutting-edge technologies to create commercial-scale radioisotopes that can detect and treat cancer once they are bonded to a molecule. With its advanced, environmentally friendly technology, dependable management team, and exceptional skills in the complex synthesis of radioisotopes, NorthStar is gaining a foothold in the rapidly developing sector of radiopharmaceutical therapy. In addition to producing copper-67 (Cu-67) on a regular basis, NorthStar is set to become the first company to generate actinium-225 (Ac-225) on a commercial scale without the need of carriers. In order to assist biopharmaceutical businesses in quickly advancing their development and commercial programs, the company’s Radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) services unit offers specialized radiopharmaceutical knowledge along with tailored service options. For additional details regarding NorthStar’s extensive offering and patient-centered services
